The expense involved in treating diabetes in the United States can be monetarily crippling, so Walmart announced a low-cost solution: analog insulin. Currently, many diabetic Americans can hardly afford to consistently purchase insulin because of its high cost which leads to many of them stretching out the time between doses—risking death—to save money and get by. Walmart's analog insulin, which will be launched as a private label product under the name ReliOn NovoLog Insulin, will offer Americans more cost-effective access to the sorely needed lifesaving treatment. The treatment targets a potential market of over 34 million Americans who suffer from diabetes. Consumers could save between $100-$250 by buying the brand's analog insulin.
The analog insulin announcement comes at a critical time for Walmart as the brand looks to expand further into the health industry. The analog insulin can be found in-store from June 24th, 2021 onward.
Image Credit: Shutterstock